Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19499329 | 0.85 | NR1H4 (0.82) | NR1H4LIFR | |
| SCHEMBL2083796 | 0.85 | NR1H4 (0.69) | NR1H4LIFR | |
| SCHEMBL1179595 | 0.84 | NR1H4 (0.77) | NR1H4LIFR | |
| SCHEMBL20094448 | 0.84 | NR1H4 (0.73) | NR1H4LIFR | |
| SCHEMBL3640196 | 0.83 | NR1H4 (0.49) | NR1H4LIFR | |
| SCHEMBL19499089 | 0.83 | NR1H4 (0.79) | NR1H4LIFR | |
| SCHEMBL4840400 | 0.83 | NR1H4 (0.69) | NR1H4LIFR | |
| SCHEMBL1179581 | 0.83 | NR1H4 (0.74) | NR1H4LIFR | |
| SCHEMBL4835579 | 0.83 | NR1H4 (0.71) | NR1H4LIFR | |
| SCHEMBL1179284 | 0.82 | NR1H4 (0.65) | NR1H4LIFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034507-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2011-02-10 | — | — | US | disclosed |
| US-20110034507-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2011-02-10 | — | — | US | disclosed |
| EP-2173174-A1 | FARNESOID X RECEPTOR AGONISTS | GlaxoSmithKline LLC (US) | 2010-04-14 | — | — | EP | disclosed |
| WO-2009005998-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-01-08 | — | — | WO | disclosed |
| WO-2009005998-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034507-A1 | FARNESOID X RECEPTOR AGONISTS | NR1H4, NR1H3, NR1H2 | NR1H4 1/4885LIFR 1950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.